We have updated our Goulamina valuation to US$130m (US$260m x 50%) and increase our target multiple for Goulamina to 0.9x from 0.5x. This increases our price target to A$0.80/sh from A$0.70/sh and we reiterate our BUY rating. Firefinch is one of our top picks among gold developers.
- Forums
- ASX - By Stock
- FFX
- Ann: Joint Venture with Ganfeng - Overview
Ann: Joint Venture with Ganfeng - Overview, page-45
Featured News
Add FFX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online